The relentless demand to accelerate drug development while upholding rigorous safety standards has pushed the clinical research industry to an inflection point, where incremental improvements are no longer sufficient. The emergence of Agentic AI represents a significant advancement in this sector,
Navigating the complex regulatory maze for a first-in-class therapy just became significantly clearer for Plus Therapeutics following a pivotal meeting with federal regulators that charted a definitive course for its lead drug candidate. The company has announced the outcomes of a constructive Type
A class of drugs once quietly confined to the clinical management of diabetes has forcefully breached the walls of traditional healthcare, creating a multi-billion dollar cultural and commercial phenomenon that is reshaping the pharmaceutical landscape. Glucagon-like peptide-1 (GLP-1) receptor
With over 250 million people living with chronic hepatitis B, the prospect of a "functional cure" has long been a distant goal. Now, with recent pivotal study results for a new therapy, that goal appears closer than ever. We sit down with Faisal Zain, a leading expert in medical
A foundational pillar of American public health, the universal childhood immunization schedule, has been abruptly dismantled, igniting a fierce debate over the safety of the nation's children and the integrity of the institutions designed to protect them. This decision has created an
A New Contender Enters the Ring: Ascletis Gains Key FDA Nod for Oral Diabetes Drug Ascletis Pharma has secured a critical milestone in the competitive metabolic disease landscape, receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This approval
